Below, we are re-publishing the news issued by ValiSeek on the 12th of December 2017
ValiSeek – Clinical Development Update on VAL401
Dr Suzy Dilly, CEO of ValiSeek provides a positive update on the clinical progress of VAL401, the anti-cancer compound. The Company has released positive formal data pertaining to disease impact. The results demonstrate that the VAL401 treatment has a statistically significant improvement in Overall Survival for patients with non-small cell lung cancer compared to those receiving no treatment.
Further information is available at: http://www.valirx.com/video/valirx-unveils-positive-results-val401-phase-ii-lung-cancer-trial/
* The study is conducted by Clinical Accelerator